Core Insights - Abbott Laboratories (ABT) is expected to report its fourth-quarter 2025 results on January 22, with adjusted earnings per share (EPS) of $1.30 in the last quarter, matching the Zacks Consensus Estimate [1] - The Zacks Consensus Estimate for revenues is $11.79 billion, indicating a 7.5% increase year-over-year, while EPS is projected to rise by 11.9% to $1.50 [2] Q4 Estimates - Revenue growth for the Diagnostics segment is anticipated to be impacted by volume-based procurement programs in China, with a projected increase of 0.8% year-over-year [3][4] - The Established Pharmaceuticals (EPD) segment is expected to show strong performance across 15 key markets, with an estimated revenue increase of 8.5% year-over-year, driven by demand in therapeutic areas such as gastroenterology and cardiometabolic [5][6] - The Medical Devices segment is projected to see a 12.5% year-over-year revenue improvement, supported by strong sales in Diabetes Care and Electrophysiology [7][13] - The Nutrition division is expected to grow by 3.3%, bolstered by new product launches in adult nutrition brands [8][15] Estimate Revision Trend - Estimates for Q4 earnings have remained unchanged at $1.50 per share over the past 30 days, indicating stability in expectations [3] Segment Performance - The Diagnostics segment's growth is likely to be sustained by global demand for routine diagnostic testing, particularly in the U.S. market [4] - The Medical Devices segment's growth is attributed to advancements in various divisions, including the launch of new products and regulatory approvals [10][12] - The Nutrition segment's growth is driven by the introduction of low-sugar formulas and new protein shakes, which are expected to enhance sales [14]

Core Insights - Abbott Laboratories (ABT) is set to report its third-quarter 2025 results on October 15, with adjusted earnings per share (EPS) of $1.26 in the last quarter, exceeding the Zacks Consensus Estimate by 0.8% [1][8] Revenue and EPS Estimates - The Zacks Consensus Estimate for Q3 revenues is $11.42 billion, reflecting a 7.4% increase from the previous year [2][8] - The Zacks Consensus Estimate for EPS is $1.30, indicating a 7.4% improvement from the prior year's figure [2][8] Segment Performance Expectations - **Diagnostics**: Revenue growth is expected to be impacted by a decline in COVID-19 testing revenues and volume-based procurement programs in China, with a projected decrease of 4.4% year over year [3][4] - **Established Pharmaceuticals (EPD)**: Strong performance is anticipated across key markets, with a year-over-year revenue increase of 9%, driven by biosimilars as a new growth pillar [5][6] - **Medical Devices**: Expected growth of 13.3% year over year, supported by the Diabetes Care division and the integration of Libre CGM data into Epic's EHR systems [6][11] - **Nutrition**: Anticipated revenue growth of 6.3% year over year, driven by strong sales of adult nutrition brands like Ensure and Glucerna [12] Recent Developments - Abbott's Structural Heart segment is expected to see growth from surgical valves and transcatheter products, bolstered by recent CE Mark and FDA approvals [9][11] - The Rhythm Management arm is gaining traction with the leadless AVEIR pacemaker, supported by favorable clinical data [10] Earnings ESP and Zacks Rank - Abbott has an Earnings ESP of 0.00% and currently holds a Zacks Rank of 3, indicating a neutral outlook for beating estimates [13]